Lactylation—a New Protein Modification That Slows Alzheimer’s?
In mice, lactylation of APP reduces amyloid deposits and slows disease progression.
In mice, lactylation of APP reduces amyloid deposits and slows disease progression.
Recent genetic and mechanistic studies on SORL1 place the endolysosomal system, in both neurons and microglia, front and center in the pathogenesis of AD.
In models of amyloidosis and tauopathy, the noble gas curbed inflammation and made microglia more phagocytic, resulting in fewer aggregates and healthier neurons.
Survey of post-translationally modified and noncoding RNA identified more than 25,000 differences between AD and control brain.
In AD brain, cells ramp up expression of herpes virus proteins. In cultured neurons, these proteins boost p-tau, which then suppresses viral proteins.
In mice, eliminating the NPC1 gene from microglia recapitulated aspects of the lysosomal storage disorder.
In lab animals, lithocholic acid replicates life-extending benefits of caloric restriction.
Dennis Selkoe offers a closing response.
Could treating Alzheimer’s disease be as simple as inhaling xenon? Data from mice support this provocative idea. Huffing xenon for 40 minutes weekly shifted microglia from pro-inflammatory to phagocytic, allowing these immune cells to better corral plaques and prevent neurite degeneration. A Phase 1 trial in healthy elderly volunteers has started.
Mutations that slow SORL1 trafficking through the cell associate with AD, and recent work helps unveil the mechanisms involved. In neurons, SORL1 deficiency hobbles endosomal network, compromising recycling of proteins such as APP and synaptic receptors. In microglia, lysosomes suffer the consequences, accumulating undigested contents as crucial proteases get trapped in the trans-Golgi network. Check out Alzforum’s update to learn more about the latest science on this massive sorting receptor.
New in last 7 days
Latest Comments